natgillin/translations-raw huggingface dataset:
The amount of the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid in the composition may be up to 2.1 mmol, such as selected from the group consisting of up to 2.1 mmol, up to 2 mmol, up to 1.9 mmol, up to 1.8 mmol, up to 1.7 mmol, up to 1.6 mmol, up to 1.5 mmol, up to 1.4 mmol, up to 1.3 mmol, up to 1.2 mmol and up to 1.1 mmol. 
Kompozicija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je količina navedene soli N- (8-(2-hidroksibenzoil)amino)kaprilne kiseline do 2.1 mmol, kao što je izabrana iz grupe koja se sastoji od do 2.1 mmol, do 2 mmol, do 1.9 mmol, do 1.8 mmol, do 1.7 mmol, do 1.6 mmol, do 1.5 mmol, do 1.4 mmol, do 1.3 mmol, do 1.2 mmol 1 do 1.1 mmol.
L is a five or six membered heteroaryl group, selected from or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. 
L je 5- ili 6-eročlana heteroarilna skupina, koja se bira između ili; ili njegova farmaceutski prihvatljiva sol ili kiselinska adicijska sol, njegova racemična smjesa ili njezini odgovarajući enantiomer i/ili optički izomer i/ili stereoizomer.
The capsule enclosing members and the capsule are geometrically arranged such that at least one of said enclosing members is engaged by the sealing member of the capsule under the effect of the fluid pressure being present between the outer surface of the capsule acting on the sealing member. 
Elementi koji obuhvaćaju čahuru i čahura su gcomctrijski smješteni tako, da je najmanje na jedan od navedenih elemenata koji obuhvaća čahuru zahvaćen materijalom za brtvljenje čahure, na koji materijal za brtvljenje djeluje fluid pod tlakom, i to fluid koji se nalazi između vanjske površine čahure i elementa za obuhvaćanje i djeluje na element koji brtvi.
Said emulsion-forming means consist of at least one stirring element 104, such as balls or the like of equal or different sizes, for increasing emulsion of liquid components when the washing and separating container 1 is subjected to stirring. In the device of the present invention, simple manual stirring of the device can afford separation of the liquid phase composed of the fluid emulsion from the solid phase composed of cells, cell fragments, cell aggregates. 
Uređaj kao što je naveden u patentnom zahtjevu 2, naznačen time da se navedena sredstva za formiranje emulzije sastoje od najmanje jednog elementa za miješanje (104) za povećanje emulzije tekućih komponenti kada je kontejner (1) za pranje i odvajanje podvrgnut mehaničkom ili manualnom miješanju, pri čemu je sila jednaka onoj koja je korištena pri manualnoj radnji dovoljna da se stvori navedena emulzija.
Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. 
Optimalna preciznost kod postizanja koncentracija lijeka unutar raspona koji polučuje učinkovitost bez toksičnosti zahtijeva režim zasnovan na kinetici dostupnosti lijeka na ciljanim mjestima.
1 shows a block diagram of a data transmission device in accordance with the invention; 
prikazuje blok dijagram naprave za prijenos podataka u skladu s izumom;
In a preferential variant, this method is characterised in that the average particle sizes of the said fractions of particles obtained in step d) differ by at least 0.1 um relative to one another. 
Postupak prema zahtjevu 1, naznačen time da se prosječne veličine čestica navedenih frakcija čestica koje su dobivene u koraku d) razlikuju za barem 0.1 pm u odnosu jedne prema drugoj.
An isolated polypeptide comprising an amino acid sequence having at least 80% homology to SEQ ID NO. 
Polipeptid pogodan za uporabu u parenteralnoj primjeni naznačen time što sadrži aminokiselinsku sekvencu koja ima najmanje 80% homologije sa SEQ ID NO.
adjusting the pH of the mixture in the API-vessel of step (k) to below 2 by using an acid, selected from a group consisting of hydrochloric acid, sulfuric acid, nitric acid and lactic acid, either singly or any combination thereof, in an amount between 0.005% (w/w) to 0.5% (w/w), 
HR P20130515 T1 podešavanje pH smjese u API-posudi iz stupnja k na ispod 2 korištenjem kiseline, odabrane iz skupine koja sadrži kiseline. kao što su na primjer HC1, H2SO4, HNO;, mliječna kiselina 1 slične, ili pojedinačno ili bilo koju njihovu kombinaciju, prvenstveno dušične kiseline u količini između 0,005% (tež.) do 0,5% (tež.), prvenstveno 0,3% (tež.), pogodnije 0,25% (tež.),
In some embodiments, R8 is H or F. Some embodiments of the present invention pertain to compounds wherein Y is NH. 
Pripravak u skladu sa zahtjevom 1 ili 2, naznačen time, da Y je NH.
Ultrasound at high power (at least 1 W/cm2) creates cavitation. 
Ultrazvuk pri višoj snazi (najmanje 1 W/cm*) stvara šupljinu.
at least one storage unit comprising several levels at which loads can be picked or deposited, 
• najmanje jedan skladišni kompleks (E1) koji ima više razina, s kojih se robu može skidati ili stavljati uz pomoć čunaka;
The polymeric composition according to claim 1, wherein the molecular weight of the vinyl aromatic polymer grafted on the olefinic elastomer is equal to that of the vinyl aromatic polymer of component (a). 
Polimerni sastav prema bilo kojem od zahtjeva od 1 do 8, naznačen time što je molekularna masa vinil aromatskog polimera cijepljenog na olefinskom elastomeru jednaka onoj vinil aromatskog polimera komponente (a).
It is an object of the invention to provide further and improved methods for the production of microfluidized oil-in-water emulsions (such as MF59), in particular methods that are suitable for use on a commercial scale and which use filtration. DISCLOSURE OF THE INVENTION The invention also provides a method for the manufacture of an oil-in-water emulsion comprising steps of: (i) preparation of a first emulsion having a first average oil droplet size of 5000 nm or less, also known as a preliminary emulsion or a pre-emulsion; (ii) microfluidization of the first emulsion to form a second emulsion having a second average oil droplet size which is less than the first average oil droplet size; and (iii) filtration of the second emulsion using a hydrophilic asymmetric membrane. 
Postupak za proizvodnju adjuvanta za cjepivo koji sadrži emulziju ulje-u-vodi koja sadrži skvalen, naznačen time da sadrži korake: (1) stvaranja emulzije koja sadrži skvalen koja ima prosječnu veličinu uljne kapljice od 500 nm ili manje i sadrži korake a. stvaranja prve emulzije koja ima prvu prosječnu veličinu uljne kapljice; b. mikrofluidizaciju prve emulzije da se formira druga emulzija koja ima drugu prosječnu veličinu uljne kapljice od 500 nm ili manje, koja je manja od prve prosječne veličine uljne kapljice; te (i) filtriranja druge emulzije korištenjem hidrofilne polietersulfonske membrane sa dvostrukim slojem, sa prvim slojem koji ima veličinu pora > 3pm i drugim slojem koji ima veličinu pora < 0.3um, te se time osigurava adjuvant za cjepivo.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least three chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, and CCL5/RANTES and which does not bind to CCL2/MCP-1 comprising a heavy and light chain CDR sequence combination (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) of SEQ ID NO: 43/44/45/48/49/50, or which competes for binding to CCL3/MIP-1a, CCL4/MIP-1B, and CCL5/RANTES, with an antibody or antigen binding fragment comprising a heavy and light chain CDR sequence combination of SEQ ID NO: 43/44/45/48/49/50. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje tri kemokinima odabrana iz skupine koju čine CCL3/MIP-1a, CCL4/MIP-1B, i CCL5/RANTES, a koji se ne veže na CCL2/MCP-1 i koji sadrže kombinacije CDR nizova teških i lakih lanaca (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) SEQ ID NO: 43/44/45/48/49/50, ili koji se natječe za vezivanje to CCL3/MIP-1a, CCL4/MIP-1B, i CCL5/RANTES, s antitijelom ili fragmentom koji veže antigen i sadrži kombinacije CDR nizova teških i lakih lanaca SEQ ID NO: 43/44/45/48/49/50.
For a compound to be considered a CB-1 antagonist, the compound must possess a CB-1 receptor binding affinity Ki less than 13000 nM. 
Spoj koji se smatra CB-1 antagonistom mora posjedovati afinitet vezanja za receptor Ki koja je manja od 13 000 nM.
covering the outer face (18) of the hollow structure (16) with a protective layer and with a waterproofing layer, 
- prekrivanje unutarnjeg sloja (18) šuplje strukture (16) zaštitnim slojem i vodootpornim slojem, HR P20160705 T1
converting the amorphous solid clopidogrel hydrogen sulfate to form 1 clopidogrel hydrogen sulfate. 
prevođenja amorfnog klopidogrel-hidrogensulfata u oblik 1 klopidogrel-hidrogensulfata.
Also according to above embodiment, the one or more antidiabetic compounds comprised in the pharmaceutical composition may optionally be selected from the group consisting of GSK-3 inhibitors, retinoid X receptor agonists, Beta-3 AR agonists, UCP modulators, antidiabetic thiazolidinediones, non-glitazone type PPAR gamma agonists, dual PPAR gamma/PPAR alpha agonists, antidiabetic vanadium containing compounds and biguanides. 
Farmaceutska kompozicija prema bilo kojem od paleninih zahtjeva 1-13, naznačena time što takav pojedinačni dozni oblik sadrži jedno ili više antidijabetičkih sredstava izabranih iz grupe koju čine inhibitori GSK-3, agonisti receptora za retinoid X, agonisti Beta-3 AR, modulatori UCP, antidijabetički tiazolidindioni, ne-glitazon tip agonisti PPAR gama, dvostruki PPAR gama/PPAR alfa agonisti, antidijabetički spojevi koji sadrže vanadij i biguanidi.
The insert for soles according to claim 1, wherein the insert for soles has a bursting strength at least equal to 8 kgf/cm2 determined according to the ASTM D3786 standard. 
Umetak za potplate u skladu s patentnim zahtjevom 1, naznačen time, da ima snagu pucanja koja je najmanje jednaka 8 kgf/cm", određeno prema standardu ASTM D3786.
A compound represented by the general formulas IA to IF: 
Spojevi su predstavljeni formulama od IA do IF R*
A process according to [7], wherein the crystallization solvent is a simple solvent of isopropyl alcohol or s-butyl alcohol, or a mixed solvent of s-butyl alcohol and water or a mixed solvent of isopropyl alcohol and water. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da je kristalizacijsko otapalo jednostavno otapalo od izopropil alkohola ili s-butil alkohola, ili miješano otapalo s-butil alkohola i vode ili miješano otapalo izopropil alkohola i vode.
Floor panel (24, 37, 41, 52, 70, 88, 97, 106, 114) as claimed in any of the foregoing claims, wherein the second locking element (32, 49, 56, 74, 92) is positioned at a distance from an upper side (48a) of the downward groove (30, 48). 
Podni panel (19, 24, 37, 41, 52, 70, 88, 97, 106, 114) prema bilo kojem od prethodno navedenih zahtjeva, naznačen time da je drugi element zaključavanja (32, 49, 56, 74, 92) smješten na udaljenosti od gornje strane (48a) dolje okrenutog utora (30, 48).
The resin is filtered, the solvent is evaporated off and the residue is dissolved in water and ethyl acetate. 
Smola je filtrirana, otapalo je upareno a ostatak je otopljen u vodi i etil-acetatu, Vodena faza je odijeljena i hiofilizirana.
Compound of the formula (II) according to claim 1, wherein the compound of the formula (II) is present in crystalline form. 
Spoj s formulom (II) prema zahtjevu 1, naznačen time da je spoj s formulom (II) prisutan u kristalnom obliku.
Use of a compound represented by the formula (I-b) defined in Claim 1 or a pharmaceutically-acceptable salt thereof for the manufacture of a therapeutic agent for the treatment of pain selected from neuropathic pain and fibromyalgia. 
Uporaba spoja predstavljenog formutom (1-b) kako je definirano u zahijevu 1, 1li njegove farmaceutski prihvatljive soli, nazaačena time, da je za proizvodnju terapeuiskog sredstva za hječenje bolova odabranih od neuropatskih bolova 1 fihronmnialgije.
determining the blood GLP-1 level in a biological sample obtained from a mammal, said mammal having been administered with a compound which stimulates functionality of the receptor in step (b); wherein the ability of the test compound to increase a blood GLP-1 level in the mammal is further indicative of the test compound being a GLP-1 secretagogue. 
(o) određivanje nivoa GLP-1 u krvi u biološkom uzorku dobivenom iz sisavca, pri čemu je navedenom sisavcu bio primjenjen spoj koji stimulira funkcionalnost receptora iz (b); pri čemu je sposobnost test spoja da poveća nivo GLP-I u krvi u sisavcu nadalje indikativna da je test spoj GLP-I sekretogog.
a paint coating and a painted finish or 
- kao premaz boje i/ili kao oslikani završetak ili
The nucleotide 2'-deoxythymidine-5'-monophosphate (dTMP), on the other hand, is produced by de novo synthesis from 2'-deoayuridine-5'-monophosphate (dUMP), a conversion catalysed by the enzyme thymidylate synthase. 
Nukelotid 2'-deoksitimidin-5'-monofosfat (TMP), u drugu ruku, proizvodi se sintezom de novo iz 2'-deoksiuridin-5'- monofosfat (UMP), konverzijom koju katalizira enzim timidilat sintaza.
is selected from optionally substituted by one, two or three R13 groups; 
OMO izborno supstituiranih s jednom, dvije ili tri skupine R'*;
said target DNA is hypermethylated in cancer cells of a patient having said cancer, and 
navedena ciljna DNA hipermetilirana u stanicama karcinoma pacijenta koji ima navedeni karcinom, i
• at least one microphone 
najmanje jedan mikrofon
A number of such intermediates are: 
(21) Broj predmeta:
The compound of Claim 1, wherein X is O. 
X se odabire između CH2 i O;
s is an integer ranging from 0 to 4; and r is an integer ranging from 0 to 5. 
s je cijeli broj u rasponu od 0 do 4; i r je cijeli broj u rasponu od 0 do 5.
Process according to any one of claims 39-43, wherein the colour intensity of the caramelised feedstock at 610 nm exceeds 0.01, preferably exceeds 0.024. 
Postupak prema bilo kojem od zahtjeva 39-43, naznačen time, što intenzitet boje karamelizirane sirovine pri 610 nm prelazi 0,01, poželjno prelazi 0,024.
The composition of claim 11 wherein the Monsel's solution has a pH of less than, or 0.5. 
Pripravak u skladu s patentnim zahtjevom 11, naznačen time, da Monselova otopina ima pH manje od 0,5 ili 0,5.
Solvates may form in stoichiometric amounts or may form from adventitious solvent or a combination of both. 
Solvati se mogu formirati u stehiometrijskim količinima ili se mogu formirati od pomoćnog otapala ili kombinacije oba.
In wet granulation, some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules. 
Tom se metodom neki, ili svi, aktivni sastojci i pomoćne tvari u obliku praška spajaju i zatim dalje miješaju u prisutnosti tekućine, obično vode, što uzrokuje nakupljanje praška u granule.
the wt human extracellular domain of PSMA having seq ID:447 on the cell surface; 
(i) ljudsku izvanstaničnu domenu PSMA divljeg tipa sa SEQ ID:447 na površini stanice;
Absolute ethanol (61) was added and the evaporation was continued until dryness. 
Dodan je apsolutni etanol (6 1) i uparavanje je nastavljeno do suhog.
The method of claim 1 wherein the reference B chain is fused at its N-terminus to a portion of the C-terminal region of HGF B chain, wherein position 494 (corresponding to wild type human HGF) of the C-terminal region is an amino acid other than arginine. 
Postupak prema zahtjevu 1, naznačen time, da je usporedbeni f lanac fuzioniran na svom N-kraju na dio C-terminalnog područja HGF (5 lanca, pri čemu položaj 494 (koji odgovara divljem tipu humanog HGF)
A winder unit (1) in accordance with any preceding claim, wherein the winder spools (4,5) are arranged in side by side arrangement an a respective guide wheel or pulley (6, 7) is positioned outwardly of each respective winder spools (4, 5). 
Jedinica za namatanje, namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se kalemi za namatanje nalaze u bok-uz-bok položaju, a odgovarajuće kolo ili kolut za vođenje (8, 9) se nalazi prema van u odnosu na odgovarajuće kaleme za namatanje (4, 5).
The locking nail system according to any of claims one to five, wherein the tip of the calcaneus-talar screws (2) is self-perforating and self-threading. 
Sustav čavla sa zaključavanjem prema bilo kojem od zahtjeva 1 do 4, pri čemu su vršci kalkaneus-talus vijaka (2) samobušeći i samourezni.
wherein Ar excludes substituted or unsubstituted indazol-3-yl and substituted or unsubstituted 1H-pyrazolo[3,4-b]pyridyl; 
pri čemu Ar isključuje supstituirani ili nesupstituirani indazol-3-il i supstituirani ili nesupstituirani 1H-pirazolo[3,4-b]piridil;
Microcarriers and Fibra-Cel® disks are thus routinely used in animal cell culture for the growth of anchorage-dependent cells and are among the established technological platforms for industrial production of proteins (see, e.g., Buck and Loh, J. Viriological Meth., 1985; Bohak et al, Biopolymers, 1987; Petti et al, Biotechnol. 
Mikronosači ili diskovi Fibra-Cel* se tako rabe rutinski u uzgoju životinjskih stanica za rast onih stanica koje potrebuju pričvršćivanje te su među uobičajenim tehnološkim platformama za industrijsku proizvodnju proteina (vidi, na primjer Buck i Loh, 1985; Bohak 1 sur., 1987; Petti i sur., 1994, Ikonomou isur., 2002).
measuring at least one further physical quantity associated with the anchoring, characterised in 
mjerenjem najmanje jedne daljnje fizikalne veličine povezane sa sidrenjem, karakteriziran
the costimulatory 4-1BB signalling region comprises the amino acid sequence of SEQ ID NO: 23; 
kostimulatorno signalno područje 4-1 BB sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 23;
Process according to claim 12, wherein the aqueous solution comprises dissolved calcium nitrate and at least a different dissolved nitrate salt, and the setting accelerator in the form of a powder comprising calcium nitrate having a water content higher than 5% by weight and lower than 20% by weight. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time, da vodena otopina sadržava otopljeni kalcij nitrat i barem jednu drugačiju otopljenu nitratnu sol te akcelerator vezivanja koji ima udjel vode veći od 5 % i manji od
64; and the VH region consists of the amino acid sequence shown in SEQ ID NO. 
(€) VH područje se sastoji od aminokiselinskog slijeda prikazanog u SEQ ID NO.
The method of claim 6, wherein said avermectin compound is ivermectin in a concentration greater than about 0.05% (w/w) in said dermatological composition. 
Uporaba prema jednom od zahtjeva 1 do 2, naznačena time da je navedeni spoj avermektina u koncentraciji većoj od oko 0.05% (tež./tež.).
Pharmaceutical compositions comprising a compound according to any one of claims 1 to 11 as well as a pharmaceutically acceptable carrier and/or adjuvant. 
Farmaceutski sastavi, naznačeni time, da sadrže spoj prema jednom od zahtjeva 1 do 11 kao 1 farmaceutski prihvatljiv nosač i/ili pomoćno sredstvo.
A composition comprising at least one compound as defined in claim 1 and at least one therapeutic agent chosen from anagrelide, hydroxyurea, P32, busulphan, aspirin, clopidogrel, a-interferon ticlopidine and dipyridamole. 
Kompozicija koja sadrži najmanje jednan spoj definiran Zahtjevom 1 ili spoj i najmanje jedan terapeutski agens koji se bira između anagrelida, hidroksiuree, P*, bisulfana, aspirina, klopidogrela, a-interferon tiklopidina i dipiridamola.
The reference signal receiving method according to claim 9, wherein the sequence number is calculated using the hopping pattern, which is defined based on a cell identification number, when the Non-CoMP mode is set. The reference signal receiving method according to claim 9, wherein the hopping pattern includes a first hopping pattern and a second hopping pattern different from the first hopping pattern, and the sequence number is calculated using the first hopping pattern when the CoMP mode is set, and is calculated using the second hopping pattern when the Non-CoMP mode is set. 
metoda naznačena time što sadrži: referiranje na pluralitet različitih obrazaca skoka imajući prvi obrazac skoka i drugi obrazac skoka za skakanje brojem Zadoff-Chu, ZC, sekvence koji se koristi za referentni signal i izračun broja sekvence ZC koristeći jedan od pluraliteta obrazaca skoka, prvi obrazac skoka koristeći se kad je CoMP način rada postavljen, i drugi obrazac skoka koristeći se kad je način rada ne-CoMP postavljen; i generiranje ZC sekvence koja se koristi za referentni signal koristeći izračunat broj ZC sekvence.
The first fuel container and the second fuel container are side-by-side arranged downstream to the sieving apparatus. 
- prvi spremnik za gorivo (3) i drugi spremnik za gorivo (4) su paralelno poredani nizvodno od aparata za prosijavanje (2);
The waxed granulation is transferred to a fluid bed granulator/dryer or trays and allowed to cool to room temperature or below. 
Voštena granulacija je prebačena u granulator/sušilo u fluidiziranom sloju ili u plitice te ostavljena da se ohladi na sobnu ili nižu temperaturu.
A therapeutically effective amount of an alpha adrenergic receptor agonist or a pharmaceutically acceptable salt thereof for use in treating purpura in a subject, wherein purpura is selected from solar purpura, actinic purpura, senile purpura, Bateman's purpura, laser-induced purpura, purpura caused by physical trauma, purpura caused by physical trauma to the skin, cutaneous vasculature, and/or surrounding tissues, purpura caused by a medical procedure, purpura caused by a surgical procedure, purpura caused by trauma not related to a medical procedure, and combinations thereof. 
HR P20190214 T1 PATENTNI ZAHTJEVI Terapeutski učinkovita količina agonista alfa adrenergijskog receptora ili njegove farmaceutski prihvatljive soli za uporabu u liječenju purpure kod subjekta, naznačena time što je purpura odabrana od solarne purpure, aktinske purpure, senilne purpure, Batemanove purpure, laserski inducirane purpure, purpure uzrokovane fizičkom traumom, purpure uzrokovane fizičkom traumom kože, kožne vaskulature, i/ili okolnih tkiva, purpure uzrokovane medicinskim postupkom, purpure uzrokovane kirurškim zahvatom i njihovim kombinacijama.
a heavy chain variable domain consisting of the sequence of amino acids set forth in SEQ ID NO: 114 and a light chain variable domain consisting of the sequence of amino acids set forth in SEQ ID NO: 115; or a variable heavy chain consisting of a sequence of amino acids that has a sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% to the heavy chain set forth in SEQ ID NO: 114 and a variable light chain consisting of a sequence of amino acids that has a sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% to the light chain set forth in SEQ ID NO: 115. The combination or combination for use of any of claims 1-14, further comprising a glucocorticoid. 
MPDL.3280A, njegov derivat ili njegov antigen-vezujući fragment, koji sadrži: teški lanac varijabilne domene koji sadrži sekvencu aminokiselina navedenu u SEQ ID NO: 1141 laki lanac varijabilne domene koji sadrži sekvencu aminokiselina navedenu u SEQ ID NO: 115; ili varijabilni teški lanac koji sadrži sekvencu aminokiselina koja ima identitet sekvence od barem 85 %, 86 %, 87 %, 88 %, 89 %, 90 %, 91 %, 92 %, 93 %, 94. %, 95 %, 96 %, 97 %, 98 % ili 99 % prema teškom lancu navedenom u SEQ ID NO: 114 i varijabilni laki lanac koji sadrži sekvencu aminokiselina koja ima identitet sekvence od barem 85 %, 86 %, 87 %, 88 %, 89 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % prema lakom lancu navedenom u SEQ ID NO: 115. Kombinacija ili kombinacija za uporabu prema bilo kojem od zahtjeva 1-14, koja nadalje sadrži glukokortikoid.
To compound 4c (300 mg, 0.5 mmol) in dichloromethane (2 mL) was added TFA (2 mL) and the reaction mixture was stirred at ambient temperature for 1 hour. 
Spoju 4c (300 mg, 0,5 mmol) u diklormetanu (2 ml) doda se TFA (2 ml), a reakcijsku smjesu miješa 1 sat na temperatura okoliša.